Since its approval by the FDA six years ago, oral disopyramide has earned a recognized role in the treatment of ventricular arrhythmias. During this time, clinical experience has refined our knowledge of this agent, allowing revision of dosing guidelines and better selection of patients. This review explores the recent therapeutic experience with disopyramide.
Get full access to this article
View all access options for this article.
References
1.
Dreifus LS, Filip Z., Sexton DM, Watanabe Y.: Electrophysiological and clinical effects of a new antiarrhythmic agent: Disopyramide . Am J Cardiol31:129, 1973 (abstract).
2.
Befeler B., Castellanos A., Wells DE, et al: Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate. Am J Cardiol35:282-287, 1975.
3.
Levites R., Anderson GJ: Electrophysiological effects of disopyramide phosphate during experimental myocardial ischemia. Am Heart J98(3):339-344, 1979.
4.
Josephson ME , Caracta AR, Lau SH, et al: Electrophysiological evaluation of disopyramide in man. Am Heart J86(6):771-780, 1973.
5.
Caracta A.: The electrophysiology of Norpace (part III). Angiology26(Suppl 1):120-123, 1975.
Spurrell Raj , Thorburn CW, Camm J., et al: Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome. Br Heart J37:861-7, 1975.
8.
Bennett DH: Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Chest74:624-8, 1978.
9.
Kerr CR, Prystowsky EN, Smith WM, Gallagher JJ: Disopyramide phosphate in Wolff-Parkinson-White syndrome. Am J Cardiol47:495, 1981 (abstract).
10.
Karim A.: The pharmacokinetics of Norpace. Angiology26: Suppl 1 (2):85-98, 1975.
11.
Befeler B.: The hemodynamic effects of Norpace (part I). Angiology26(Suppl 1):99-101, 1975.
12.
Willis PW: The hemodynamic effects of Norpace (part II). Angiology26(Suppl 1):102-110, 1975.
13.
Hulting J., Rosenhamer G.: Antiarrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia. J Int Med Res4(Suppl 1):90-95, 1976.
14.
Hulting J., Jansson B.: Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide . Eur J Cardiol11:91-99, 1977.
15.
Smith WS, Vismara L., Kalmansohn RB, et al: Clinical studies of Norpace. Angiology26(Suppl 1):124-153, 1975.
16.
Ryan MJ, Temte J., Lown B.: Evaluation of a new antiarrhythmic agent, disopyramide phosphate. Circulation49-50(Suppl 3):79, 1974.
17.
Niarchos AP : Disopyramide: Serum level and arrhythmia conversion . Am Heart J92(1):57-64, 1976.
18.
Oshrain C., Arif M., Laidlaw JC, et al: A double-blind comparison of disopyramide phosphate and quinidine sulfate as antiarrhythmic agents. Report from scientific exhibit, American Heart Association, 40th Scientific Sessions, November 15-18, 1976.
19.
Jobst C., Enenkel W.: Vergleichsstudie zwischen Disopyramid und Procainamid Hcl per os in Fallen mit Extrasystolen. Herz Kreislauf Gesam Ges Exp Med DDR10:30-33, 1978.
20.
Stauch M., Grewe N., Nissen H.: Wirkung von Disopyramid-Phosphat bei Extrasystolie in Ruhe und unter Belastung . Munchen Med Wochschr118:331-334, 1976.
21.
Benditt DG, Pritchett Elc, Wallace AG, Gallagher JJ: Recurrent ventricular tachycardia in man: Evaluation of disopyramide therapy by intracardiac electrical stimulation. Eur J Cardiol9:255-276, 1979.
22.
Denes P., Wu D., Wyndham C., et al: Chronic longterm electrophysiologic study of paroxysmal ventricular tachycardia. Chest77(4):478-487, 1980.
23.
Jennings G. , Jones Mbs, Besterman Emm, et al: Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction. Lancet1:51-54, 1976.
24.
Zainal N., Carmichael Djs, Griffiths JW, et al: Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards. Lancet2:887-889, 1977.
25.
Nicholls DP , Haybyrne T., Barnes PC: Intravenous and oral disopyramide after myocardial infarction. Lancet2:936-938, 1980.
26.
Wilcox RG, Hampton JR, Rowley JM, et al: Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction . Lancet2:765-769, 1980.
27.
Ward JW: Arrhythmia prevention in early myocardial infarction. Lancet1:1006, 1977.
28.
Kidner PH, Carmichael Djs: The effects of disopyramide in the prevention of ventricular irritability following acute myocardial infarction. J Irish Med Assoc70(Suppl to number 14):22, 1977.
29.
Heel RC, Brogden RN, Speight RM, Avery GS: Disopyramide: A review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs15:331-368, 1978.
30.
Kumana CR, Rambihar VS, Tanser PH, et al: A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction. Br J Clin Pharm14:519-527, 1982.
31.
Hartel G., Louhija A., Konttinen A.: Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Therapeut15(6):551-555, 1974.
32.
Swiryn S., Bauernfeind RA, Wyndham Crc, et al: Effects of oral disopyramide phosphate on induction of paroxysmal supraventricular tachycardia. Circulation64(1):169-175, 1981.
33.
Pollick C.: Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide . N Engl J Med307(16):997-999, 1982.
34.
Quevedo SF, Krauss DS, Chazan JA, et al: Fasting hypoglycemia secondary to disopyramide therapy. JAMA245(23):2424, 1981.
35.
Goldberg IJ , Brown LK, Rayfield EJ: Disopyramide (Norpace®)-induced hypoglycemia . Am J Med69:463-6, 1980.
36.
Story JR, Abdulla AM, Frank MJ: Cardiogenic shock and disopyramide phosphate. JAMA242(7):654-655, 1979.
Kinney EL, Field EH, Salmon MP, Zelis R.: Cardiac arrhythmias associated with disopyramide. N Engl J Med302:1146, 1980.
39.
Podrid PJ, Schoeneberger A., Lown B.: Congestive heart failure caused by oral disopyramide. N Engl J Med302(11):614-617, 1980.
40.
Gottdiener JS, DiBianco R., Fletcher RD: Effects of antiarrhythmic agents on cardiac function. Angiology33:228-238, 1982 (abstract).
41.
Kowey PR, Friedman PL, Podrid PJ, et al: Use of radionuclide ventriculography for assessment of changes in myocardial performance induced by disopyramide phosphate. Am Heart J104(4):769-774, 1982.
42.
Cathcart-Rake WF, Coker JE, Atkins FL, et al: The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men. Circulation61(5):938-945, 1980.
43.
Velebit V., Podrid PJ, Graboys TB, Lown B.: Aggravation of ventricular arrhythmia by antiarrhythmic drugs. Am J Cardiol43:359, 1979 (abstract).
44.
Montgomery BJ: Antiarrhythmic agents may cause sudden death; drug testing urged. JAMA241(17):1771, 1979.
45.
Leahey EB, Reiffel JA, Giardino EV, Bigger JT: The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin . Ann Intern Med92:605-608, 1980.
46.
Wellens Hjj , Gorgels AP, Braat SJ, et al: Effect of oral disopyramide on serum digoxin levels. A prospective study. Am Heart J100(6):934-935, 1980.
47.
Aitio M-L., Mansury L., Tala E., et al: The effect of enzyme induction on the metabolism of disopyramide in man. Br J Clin Pharm11:279-285, 1981.
48.
Koch-Weser J.: Drug therapy: Disopyramide. N Engl J Med300(17):957-962, 1979.
49.
Mason DT: Disopyramide: A new agent for effective therapy of ventricular arrhythmias . Drugs15:329-330, 1978.
50.
Vera Z., Mason DT, Awan NA, Amsterdam EA: The newer antiarrhythmics: Disopyramide. Drug Therapy10(9):57-66, 1980.
